PMID- 12427361
OWN - NLM
STAT- MEDLINE
DCOM- 20030505
LR  - 20191106
IS  - 1523-3774 (Print)
IS  - 1523-3774 (Linking)
VI  - 4
IP  - 6
DP  - 2002 Dec
TI  - Update on the treatment of Kawasaki disease in childhood.
PG  - 474-82
AB  - Intravenous immunoglobulin (IVIG) treatment for Kawasaki disease (KD), first 
      discovered almost 20 years ago, dramatically changed the management and prognosis 
      of the condition. Although standard Japanese Ministry of Health criteria suggest 
      that current treatment is more than 95% effective at preventing coronary artery 
      changes, echocardiographic measurements adjusted for body size, imply a far 
      higher incidence of coronary artery dilitation despite prompt therapy. If one 
      also considers data on chronic alterations in endothelial function after KD, then 
      more effective approaches to the management of acute and recurrent KD are needed. 
      A variety of possible adjunct therapies--most notably high-dose 
      corticosteroids--currently are being studied to determine whether better 
      long-term outcomes may be achieved than with IVIG alone.
FAU - Sundel, Robert P
AU  - Sundel RP
AD  - Department of Medicine, Rheumatology Program, Children's Hospital and Department 
      of Pediatrics, Harvard Medical School, 300 Longwood Avenue, Boston, MA 02115, 
      USA. Robert.Sundel@tch.harvard.edu
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Rheumatol Rep
JT  - Current rheumatology reports
JID - 100888970
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoglobulin Fab Fragments)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - R16CO5Y76E (Aspirin)
RN  - X4W7ZR7023 (Methylprednisolone)
RN  - X85G7936GV (Abciximab)
SB  - IM
MH  - Abciximab
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Aspirin/therapeutic use
MH  - Child
MH  - Humans
MH  - Immunoglobulin Fab Fragments/therapeutic use
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Methylprednisolone/therapeutic use
MH  - Mucocutaneous Lymph Node Syndrome/classification/diagnosis/*drug therapy
MH  - Plasmapheresis
MH  - Salvage Therapy
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
RF  - 60
EDAT- 2002/11/13 04:00
MHDA- 2003/05/06 05:00
CRDT- 2002/11/13 04:00
PHST- 2002/11/13 04:00 [pubmed]
PHST- 2003/05/06 05:00 [medline]
PHST- 2002/11/13 04:00 [entrez]
AID - 10.1007/s11926-002-0053-6 [doi]
PST - ppublish
SO  - Curr Rheumatol Rep. 2002 Dec;4(6):474-82. doi: 10.1007/s11926-002-0053-6.